Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. Sells 2,200 Shares

Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction dated Thursday, April 10th. The shares were sold at an average price of $70.22, for a total value of $154,484.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Daniel N. Swisher, Jr. also recently made the following trade(s):

• On Monday, February 10th, Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock. The shares were sold at an average price of $68.08, for a total transaction of $149,776.00.

Corcept Therapeutics Price Performance

CORT stock traded down $2.36 during midday trading on Friday, reaching $62.24. The stock had a trading volume of 1,579,046 shares, compared to its average volume of 1,131,594. Corcept Therapeutics Incorporated has a 52-week low of $20.84 and a 52-week high of $117.33. The company has a market cap of $6.57 billion, a price-to-earnings ratio of 49.40 and a beta of 0.15. The company's fifty day simple moving average is $65.44 and its 200 day simple moving average is $58.39. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share for the quarter, missing analysts' consensus estimates of $0.37 by ($0.11). The business had revenue of $181.89 million for the quarter, compared to analyst estimates of $200.12 million. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. As a group, sell-side analysts predict that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

CORT has been the subject of a number of analyst reports. Truist Financial upped their price objective on shares of Corcept Therapeutics from $76.00 to $150.00 and gave the stock a "buy" rating in a research report on Monday, March 31st. StockNews.com downgraded Corcept Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, February 28th. HC Wainwright upped their target price on Corcept Therapeutics from $115.00 to $150.00 and gave the stock a "buy" rating in a research note on Monday, March 31st. Canaccord Genuity Group lifted their price target on shares of Corcept Therapeutics from $130.00 to $142.00 and gave the company a "buy" rating in a research note on Tuesday, April 1st. Finally, Piper Sandler increased their price objective on shares of Corcept Therapeutics from $128.00 to $131.00 and gave the company an "overweight" rating in a report on Thursday, April 3rd. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Corcept Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $143.25.

Hedge Funds Weigh In On Corcept Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CORT. Kestra Investment Management LLC acquired a new stake in shares of Corcept Therapeutics in the 4th quarter worth $27,000. MassMutual Private Wealth & Trust FSB grew its holdings in shares of Corcept Therapeutics by 102.0% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 620 shares of the biotechnology company's stock valued at $71,000 after purchasing an additional 313 shares during the period. Canada Pension Plan Investment Board acquired a new stake in Corcept Therapeutics during the fourth quarter worth about $40,000. National Bank of Canada FI purchased a new position in Corcept Therapeutics during the fourth quarter worth about $42,000. Finally, USA Financial Formulas purchased a new position in Corcept Therapeutics during the fourth quarter worth about $54,000. Hedge funds and other institutional investors own 93.61% of the company's stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.